Cargando…
Evolution of Molecular Targeted Cancer Therapy: Mechanisms of Drug Resistance and Novel Opportunities Identified by CRISPR-Cas9 Screening
Molecular targeted therapy has revolutionized the landscape of cancer treatment due to better therapeutic responses and less systemic toxicity. However, therapeutic resistance is a major challenge in clinical settings that hinders continuous clinical benefits for cancer patients. In this regard, unr...
Autores principales: | , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8970599/ https://www.ncbi.nlm.nih.gov/pubmed/35372044 http://dx.doi.org/10.3389/fonc.2022.755053 |
_version_ | 1784679491267723264 |
---|---|
author | Hou, Jue He, Zongsheng Liu, Tian Chen, Dongfeng Wang, Bin Wen, Qinglian Zheng, Xi |
author_facet | Hou, Jue He, Zongsheng Liu, Tian Chen, Dongfeng Wang, Bin Wen, Qinglian Zheng, Xi |
author_sort | Hou, Jue |
collection | PubMed |
description | Molecular targeted therapy has revolutionized the landscape of cancer treatment due to better therapeutic responses and less systemic toxicity. However, therapeutic resistance is a major challenge in clinical settings that hinders continuous clinical benefits for cancer patients. In this regard, unraveling the mechanisms of drug resistance may identify new druggable genetic alterations for molecularly targeted therapies, thus contributing to improved therapeutic efficacies. The recent rapid development of novel methodologies including CRISPR-Cas9 screening technology and patient-derived models provides powerful tools to dissect the underlying mechanisms of resistance to targeted cancer therapies. In this review, we updated therapeutic targets undergoing preclinical and clinical evaluation for various cancer types. More importantly, we provided comprehensive elaboration of high throughput CRISPR-Cas9 screening in deciphering potential mechanisms of unresponsiveness to molecularly targeted therapies, which will shed light on the discovery of novel opportunities for designing next-generation anti-cancer drugs. |
format | Online Article Text |
id | pubmed-8970599 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | Frontiers Media S.A. |
record_format | MEDLINE/PubMed |
spelling | pubmed-89705992022-04-01 Evolution of Molecular Targeted Cancer Therapy: Mechanisms of Drug Resistance and Novel Opportunities Identified by CRISPR-Cas9 Screening Hou, Jue He, Zongsheng Liu, Tian Chen, Dongfeng Wang, Bin Wen, Qinglian Zheng, Xi Front Oncol Oncology Molecular targeted therapy has revolutionized the landscape of cancer treatment due to better therapeutic responses and less systemic toxicity. However, therapeutic resistance is a major challenge in clinical settings that hinders continuous clinical benefits for cancer patients. In this regard, unraveling the mechanisms of drug resistance may identify new druggable genetic alterations for molecularly targeted therapies, thus contributing to improved therapeutic efficacies. The recent rapid development of novel methodologies including CRISPR-Cas9 screening technology and patient-derived models provides powerful tools to dissect the underlying mechanisms of resistance to targeted cancer therapies. In this review, we updated therapeutic targets undergoing preclinical and clinical evaluation for various cancer types. More importantly, we provided comprehensive elaboration of high throughput CRISPR-Cas9 screening in deciphering potential mechanisms of unresponsiveness to molecularly targeted therapies, which will shed light on the discovery of novel opportunities for designing next-generation anti-cancer drugs. Frontiers Media S.A. 2022-03-17 /pmc/articles/PMC8970599/ /pubmed/35372044 http://dx.doi.org/10.3389/fonc.2022.755053 Text en Copyright © 2022 Hou, He, Liu, Chen, Wang, Wen and Zheng https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. |
spellingShingle | Oncology Hou, Jue He, Zongsheng Liu, Tian Chen, Dongfeng Wang, Bin Wen, Qinglian Zheng, Xi Evolution of Molecular Targeted Cancer Therapy: Mechanisms of Drug Resistance and Novel Opportunities Identified by CRISPR-Cas9 Screening |
title | Evolution of Molecular Targeted Cancer Therapy: Mechanisms of Drug Resistance and Novel Opportunities Identified by CRISPR-Cas9 Screening |
title_full | Evolution of Molecular Targeted Cancer Therapy: Mechanisms of Drug Resistance and Novel Opportunities Identified by CRISPR-Cas9 Screening |
title_fullStr | Evolution of Molecular Targeted Cancer Therapy: Mechanisms of Drug Resistance and Novel Opportunities Identified by CRISPR-Cas9 Screening |
title_full_unstemmed | Evolution of Molecular Targeted Cancer Therapy: Mechanisms of Drug Resistance and Novel Opportunities Identified by CRISPR-Cas9 Screening |
title_short | Evolution of Molecular Targeted Cancer Therapy: Mechanisms of Drug Resistance and Novel Opportunities Identified by CRISPR-Cas9 Screening |
title_sort | evolution of molecular targeted cancer therapy: mechanisms of drug resistance and novel opportunities identified by crispr-cas9 screening |
topic | Oncology |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8970599/ https://www.ncbi.nlm.nih.gov/pubmed/35372044 http://dx.doi.org/10.3389/fonc.2022.755053 |
work_keys_str_mv | AT houjue evolutionofmoleculartargetedcancertherapymechanismsofdrugresistanceandnovelopportunitiesidentifiedbycrisprcas9screening AT hezongsheng evolutionofmoleculartargetedcancertherapymechanismsofdrugresistanceandnovelopportunitiesidentifiedbycrisprcas9screening AT liutian evolutionofmoleculartargetedcancertherapymechanismsofdrugresistanceandnovelopportunitiesidentifiedbycrisprcas9screening AT chendongfeng evolutionofmoleculartargetedcancertherapymechanismsofdrugresistanceandnovelopportunitiesidentifiedbycrisprcas9screening AT wangbin evolutionofmoleculartargetedcancertherapymechanismsofdrugresistanceandnovelopportunitiesidentifiedbycrisprcas9screening AT wenqinglian evolutionofmoleculartargetedcancertherapymechanismsofdrugresistanceandnovelopportunitiesidentifiedbycrisprcas9screening AT zhengxi evolutionofmoleculartargetedcancertherapymechanismsofdrugresistanceandnovelopportunitiesidentifiedbycrisprcas9screening |